MET and gastric cancer: Studies based on fluorescence in situ hybridization (FISH) analysis have identified MET amplification in up to ~5% of patients with NSCLC [24,25,26,27] or gastric cancer [20,28,29], whereas an increase in MET copy number was found in up to ~20% of NSCLC [30,31,32,33,34,35] and gastric cancer [36,37,38,39,40] patients by Southern blot analysis or with a polymerase chain reaction (PCR)-based assay.